Arvinas
vepdegestrant (ARV-471) is a first-in-class estrogen-receptor PROTAC approaching FDA approval for ER+ breast cancer, co-developed with Pfizer; it is the modality's lead regulatory asset and would be the first approved targeted-protein-degradation drug.
- Country
- United States
- Ticker
- ARVN
ER PROTAC (vepdegestrant)
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| PROTACs (targeted protein degradation) | therapeutics-platforms | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.